AstraZeneca’s Sone-Ve improves overall survival in Phase III gastric cancer trial

By Public Technologies
  • AstraZeneca will present overall survival data from four pivotal Phase III trials at the ESMO Congress, October 23-27, 2026.
  • CLARITY-Gastric01 showed Sone-Ve improved survival versus investigator-selected therapy in previously treated patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer.
  • SAFFRON results will highlight the clinical benefit of adding Orpathys to Tagrisso in previously treated, MET-driven, EGFR-mutated lung cancer.
  • VOLGA and DeLLphi-305 findings will showcase Imfinzi combinations’ potential to improve treatment in bladder cancer and extensive-stage small cell lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202610190206BITN____UKPR__SV_20261018-BIT-4883-0) on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk